Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder Therapeutics Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.
The autism spectrum disorder therapeutics market size attained a value of USD 2.11 Billion in 2024, driven by the increasing research and development aided by the government and industrial players, and a growing pipeline of autism spectrum disorder drugs across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to attain a value of USD 3.81 Billion by 2034. 
The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.
Autism Spectrum Disorder Therapeutics Market Growth Drivers
Rising Number of Pipeline Drugs Expected to Propel Market Growth
The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1.
The trials will allow the application of the company's precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.
Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand
In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd, announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmideT (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD).
The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.
Autism Spectrum Disorder Therapeutics Market Trends
Advancement in Diagnostic Tools
The rising advancement in diagnostic tools and techniques that enable earlier detection of autism spectrum disorder is a major trend that stimulates the demand for the therapeutics market. Further, increased implementation of screening programs, particularly in schools and pediatric practices, is resulting in early diagnosis and timely intervention.
Development of Behavioral Therapies
The rising focus on the development of behavioral therapies is a major market trend. Behavioral therapies including applied behavior analysis (ABA) and cognitive-behavioral therapy (CBT) are increasingly being integrated into treatment plans and are poised to boost the autism spectrum disorder therapeutics market share.
Rising Adoption of Telemedicine and Digital Health Platforms
The market is experiencing a rising adoption of telemedicine and digital health platforms which has expanded access to care for individuals with autism spectrum disorder, particularly those living in underserved areas. The increasing remote access to care is expected to augment the market demand in the forecast period.
Increased Awareness Campaigns
Increased public campaigns and advocacy efforts are leading to greater acceptance of autism spectrum disorder, which is resulting in early diagnosis of the affected patients. In addition, advocacy groups and several foundations are offering considerable funding and support for ASD research and treatment development, which directly impacts the market dynamics.
Key Questions Answered in the Autism Spectrum Disorder Therapeutics Market Report
- What was the autism spectrum disorder therapeutics market value in 2024?
- What is the autism spectrum disorder therapeutics market forecast outlook for 2025-2034?
- What are the regional markets covered in the report?
- What is market segmentation based on disease type?
- What is the market breakup based on treatment type?
- What is the market breakup by age group?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the autism spectrum disorder therapeutics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of autism spectrum disorder affect the market landscape?
- What are the major autism spectrum disorder therapeutics market trends?
- Which disease type will dominate the market share?
- Which treatment type is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which age group is projected to contribute to the highest market growth?
- Who are the key players involved in the autism spectrum disorder therapeutics market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 400 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value (USD) in 2025 | $2.11 Billion |
| Forecasted Market Value (USD) by 2034 | $3.81 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
Supplier Landscape
- Abbvie Inc
- Jazz Pharmaceuticals
- Novartis AG
- Johnson & Johnson Services, Inc.
- Curemark LLC
- Bristol Myers Squibb Co .
- Axial therapeutics
- Q BioMed Inc .
- PaxMedica
- Otsuka Pharmaceutica
- Stalicla SA
- Zynerba Pharmaceuticals, Inc
Autism Spectrum Disorder Therapeutics Market Segmentation
Market Breakup by Disease Type
- Autistic Disorder
- Asperger's Syndrome
- Pervasive Development Disorder (PDD)
- Others
Market Breakup by Treatment Type
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
Market Breakup by Age Group
- Child
- Adult
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
For more information about this report visit https://www.researchandmarkets.com/r/tyy10y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
